Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.26%||163.37||0.7%||$1368.59m|
|MRK||Merck & Co., Inc.||-1.55%||72.28||0.7%||$1045.98m|
|BMY||Bristol-Myers Squibb Co.||0.50%||57.12||1.0%||$821.40m|
|LLY||Eli Lilly & Co.||-0.47%||245.18||1.1%||$704.90m|
|DRNA||Dicerna Pharmaceuticals, Inc.||-0.05%||38.16||0.3%||$155.25m|
|RPRX||Royalty Pharma Plc||1.74%||38.55||0.1%||$119.40m|
|NVO||Novo Nordisk A/S||2.24%||110.16||0.1%||$84.66m|
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.